|
|
||||||||
J Thorac Cardiovasc Surg 2008;135:405-411
© 2008 The American Association for Thoracic Surgery
Cardiopulmonary Support and Physiology |
a Henry Low Heart Center, Hartford Hospital, Hartford, Conn
b University of Connecticut School of Pharmacy, Cardiac Pharmacology Service, Divisions of Cardiology and Drug Information, Hartford, Conn
c University of Connecticut School of Medicine, Department of Internal Medicine, Hartford Hospital, Hartford, Conn
d Divisions of Cardiology and Cardiothoracic Surgery, Hartford Hospital, Hartford, Conn
e University of Connecticut School of Pharmacy, Storrs, Conn
Received for publication April 5, 2007; revisions received August 21, 2007; accepted for publication August 30, 2007. * Address for reprints: Craig I. Coleman, PharmD, University of Connecticut School of Pharmacy, Pharmacy Practice, 80 Seymour Street, CB309, Hartford, CT 06102. (Email: ccolema{at}harthosp.org).
Objective: Recent studies have suggested that statins reduce atrial fibrillation after cardiothoracic surgery, but the use of proven prophylactic strategies such as beta-blockers and amiodarone in these studies was not provided. Therefore, we sought to determine whether preoperative statin use could reduce the incidence of post-cardiothoracic surgery atrial fibrillation in a population who already had a high background use of beta-blockers and appreciable use of prophylactic amiodarone.
Methods: Patients undergoing cardiothoracic surgery from the randomized, controlled Atrial Fibrillation Suppression Trials I, II, and III were evaluated in this nested cohort evaluation. The patients' demographics, surgical characteristics, medication use, and incidence of post-cardiothoracic surgery atrial fibrillation (atrial fibrillation >5 minutes duration) were uniformly and prospectively collected as part of Atrial Fibrillation Suppression Trials I, II, and III. Multivariate logistic regression was used to calculate adjusted odds ratios with 95% confidence intervals.
Results: Overall, 331 patients (59.6%) received a statin preoperatively and 224 patients (40.4%) did not. The study population had an average age of 67.8 ± 8.6 years, 77.1% were male, 14.6% had valve surgery, 6.1% had a history of atrial fibrillation, 12.6% had a history of heart failure, 84.0% received postoperative beta-blockade, and 44.1% received postoperative prophylactic amiodarone. In total, 174 patients (31.4%) developed post-cardiothoracic surgery atrial fibrillation. Upon multivariate logistic regression, statin use was associated with a reduction in post-cardiothoracic surgery atrial fibrillation (adjusted odds ratio: 0.60; 95% confidence interval 0.37–0.99). Higher intensity statin dosing (equivalent of
40 mg of atorvastatin) seemed to be associated with the greatest reductions in post-cardiothoracic surgery atrial fibrillation (adjusted odds ratio: 0.45; 95% confidence interval 0.21–0.99).
Conclusions: In a population with appreciable beta-blocker and amiodarone use, adjunctive preoperative statin use was still associated with a 40% reduction in patients' odds of developing post-cardiothoracic surgery atrial fibrillation.
This article has been cited by other articles:
![]() |
A. Anselmi, G. Possati, and M. Gaudino Postoperative inflammatory reaction and atrial fibrillation: simple correlation or causation? Ann. Thorac. Surg., July 1, 2009; 88(1): 326 - 333. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. L. Baker, M. W. Anglade, E. L. Baker, C. M. White, J. Kluger, and C. I. Coleman Use of N-acetylcysteine to reduce post-cardiothoracic surgery complications: a meta-analysis Eur. J. Cardiothorac. Surg., March 1, 2009; 35(3): 521 - 527. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Kaireviciute, A. Aidietis, and G. Y.H. Lip Atrial fibrillation following cardiac surgery: clinical features and preventative strategies Eur. Heart J., February 2, 2009; 30(4): 410 - 425. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. A. Mannacio, D. Iorio, V. De Amicis, F. Di Lello, and F. Musumeci Effect of rosuvastatin pretreatment on myocardial damage after coronary surgery: a randomized trial. J. Thorac. Cardiovasc. Surg., December 1, 2008; 136(6): 1541 - 1548. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kourliouros, N. Roberts, and M. Jahangiri Statins with equivalent lipid-lowering capacity exhibit differential effects on atrial fibrillation after cardiac surgery. J. Thorac. Cardiovasc. Surg., October 1, 2008; 136(4): 1100 - 1101. [Full Text] [PDF] |
||||
![]() |
C. I. Coleman Reply to the Editor: J. Thorac. Cardiovasc. Surg., October 1, 2008; 136(4): 1101 - 1101. [Full Text] [PDF] |
||||
![]() |
P. Dorian and B. N. Singh Upstream therapies to prevent atrial fibrillation Eur. Heart J. Suppl., September 1, 2008; 10(suppl_H): H11 - H31. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. J. Liakopoulos, Y.-H. Choi, P. L. Haldenwang, J. Strauch, T. Wittwer, H. Dorge, C. Stamm, G. Wassmer, and T. Wahlers Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing cardiac surgery: a meta-analysis of over 30 000 patients Eur. Heart J., June 2, 2008; 29(12): 1548 - 1559. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |